logo-loader

MGC Pharmaceuticals says CimetrA has wide ranging applications

Published: 13:09 27 Jun 2022 BST

MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) is confident its CimetrA treatment has wide-ranging applications.

As such the company is now advancing the treatment which was originally designed to evaluate the efficacy and safety of a treatment for COVID-19.

Chief medical officer Nadya Lisovoder tells Proactive that a recent pre-clinical trial has opened up new opportunities for the treatment, and the next steps may include a focus on rheumatoid arthritis “because of the huge market size and unmet needs.”

Immunic Therapeutics reaches major milestone with completion of ENSURE Trial...

Immunic Therapeutics Chief Medical Officer Dr Andreas Muehler joined Steve Darling from Proactive to announce two major developments for the company’s lead drug candidate, vidofludimus calcium (IMU-838)—a nuclear receptor-related 1 (Nurr1) activator currently being investigated for the treatment...

3 days ago
OSZAR »